$190.0$152.025.0%Testim Ex – U.S. & Contract Revenue
3.08.5(64.2%)Total Testim Revenue
$193.0$160.520.3%XIAFLEX U.S. Revenue
$14.1n/an/aXIAFLEX Contract Revenue
4.33.622.1%Total XIAFLEX Revenue
$18.4$3.6416.7%Total Worldwide Revenue
$211.4$164.028.9%Contract Revenues represent amortization of previously received upfront and milestone payments.
2011 XIAFLEX Net Revenue GuidanceFor 2011, Auxilium anticipates that 2011 XIAFLEX net revenues will be in the range of $55.0 to $67.0 million, including approximately $50.0 to 60.0 million in U.S. revenue, and $5.0 to 7.0 million in revenue recognized from royalties and milestones under the Pfizer contract.
Upcoming Investor PresentationAuxilium reported these numbers in advance of a presentation to investors tomorrow, January 11, 2011 at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, when Auxilium's Chief Executive Officer and President, Armando Anido, will outline the Company's strategic priorities.
Mr. Anido will speak at 4:00 p.m. PT (7:00 p.m. ET) tomorrow, and his remarks will be webcast via a link on the "For Investors" section of www.auxilium.com. Mr. Anido will give an overview of the Auxilium current business strategy, which will focus on the following areas:
A PDF of the presentation slides to be used during the remarks is now available on the "For Investors" section of the Auxilium web site under the "Presentations" tab. A question and answer session will follow tomorrow's presentation and will also be webcast. The presentation webcast, the presenta
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved